OSLO, Norway--(BUSINESS WIRE)--OncoImmunity has become the first company to obtain a CE-IVD mark for the clinical use of a machine-learning based neoantigen prediction technology. This quality ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback